Cargando…

Different onset patterns of monthly paliperidone palmitate in hospitalised patient diagnosed with schizophrenia

AIMS: Paliperidone palmitate long-acting injectable (PPLAI) initially requires two loading doses of 150 and 100 mg on days 1 and 8 (± 4 days) intramuscularly. In clinical practice, different PPLAI initiation patterns have been observed. The aim of this study is to describe different PPLAI onset patt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrera-Sánchez, Javier, Aznar, Julia, Izaguirre, Leire, Ovejero, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Psychopharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770760/ http://dx.doi.org/10.1192/bjo.2021.459

Ejemplares similares

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Potential drug targets in the kynurenine pathway to treat acute schizophrenia
por: Malhotra, Ayush, et al.
Publicado: (2021)

Predictors of transition from paliperidone palmitate 1 and 3 months (PP1M & PPP3M) to paliperidone palmitate 6 months (PP6M)
por: Escobedo-Aedo, P. J., et al.
Publicado: (2023)

Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
por: Hargarter, L, et al.
Publicado: (2016)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa, Jennifer Kern, et al.
Publicado: (2012)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang, Fan, et al.
Publicado: (2015)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2023)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si, Tianmei, et al.
Publicado: (2019)

Adjunct pharmacotherapy for psychotherapy
por: Lochtenberg, Jessica, et al.
Publicado: (2021)

Peripheral cortisol administration blunts reward arousal but heightens anxiety-like arousal in marmosets
por: Alexander, Laith, et al.
Publicado: (2021)

Psilocybin: the magic medicine for depression?
por: Corrigan, Amber Elyse, et al.
Publicado: (2021)

Comparison between the efficiency of pharmacotherapy and cognitive behavioral therapy in reducing captagon (fenethylline) dependence and relapse prevention
por: Binnwejim, Mohammed, et al.
Publicado: (2021)

A narrative review of the pharmacological management of psychosis in Alzheimer's disease
por: Matthews, Alexander, et al.
Publicado: (2021)

Multicentre evaluation of the pharmacological management of women with bipolar disorder in the perinatal period
por: Dias, Marisa Casanova, et al.
Publicado: (2021)

The links between the amount of antipsychotic medication prescribed at GP practice level, local demographic factors and medication selection
por: Heald, Adrian, et al.
Publicado: (2021)

Buspirone in obsessive-compulsive disorder: a potential dark horse?
por: Garg, Kabir, et al.
Publicado: (2021)

'Just Say No' (Or at Least Ask Why) STOMP Medication Reviews in Tower Hamlets Community Learning Disability Service
por: Jones, Anthony, et al.
Publicado: (2022)

Assessment of Legibility and Completeness of Prescriptions at Tertiary Care Hospitals: A Cross-Sectional Study
por: Saeed, Sajeel, et al.
Publicado: (2022)

What Is the Evidence for Using Anti-Epileptic Drugs to Treat Agitation and Irritability in Huntington's Disease?
por: Leong, Kok Keong, et al.
Publicado: (2022)

Improving quantification of anticholinergic burden using the Anticholinergic Effect on Cognition Scale – a healthcare improvement study in a geriatric ward setting
por: Balasundaram, Bharathi, et al.
Publicado: (2022)

Challenges of Chemsex in Health, Justice, and Social Care Settings: Developing a Coordinated Response
por: Hillier, Bradley, et al.
Publicado: (2023)

The Effects of Rivastigmine on Neuropsychiatric Symptoms in the Early Stages of Parkinson's Disease: A Systematic Review
por: Reilly, Siobhan, et al.
Publicado: (2023)

Rapid Clozapine Blood Level Determination in a National Health Service Trust
por: Taylor, David, et al.
Publicado: (2023)

Testogel Application in the Menopause: Making a Difference to the Lives of Women
por: Heald, Adrian, et al.
Publicado: (2023)

Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting
por: Tewari, Abhinav, et al.
Publicado: (2023)

The Impact of Prophylactic Medication Use on the Recurrence of Bipolar Episodes in the BDRN Pregnancy Study
por: Dias, Marisa Casanova, et al.
Publicado: (2023)

Developing a New Lithium Policy
por: Wong, Brandon, et al.
Publicado: (2023)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
por: Bell Lynum, Karimah S., et al.
Publicado: (2018)

Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
por: Pai, Nagesh, et al.
Publicado: (2018)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

Management of cognitive and negative symptoms in schizophrenia
por: Maroney, Megan
Publicado: (2022)

Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial
por: Bossie, Cynthia A., et al.
Publicado: (2011)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash, Abigail I, et al.
Publicado: (2019)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez, Alicia, et al.
Publicado: (2019)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews, Maju, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_abd7rb9n7c4vdou0mtcat048dv